Treatment of secondary acute myeloid leukemia [7]

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 926-927

  Pulsoni, Alessandro ^a   Pagano, Livio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CLINICAL TRIAL; HUMAN; LETTER; LEUKOCYTE COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; GENETICS; MORTALITY; NOTE; SECOND CANCER;

HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; NEOPLASMS, SECOND PRIMARY;

EID: 14144249271     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.202     Document Type: Letter

References (5)

1. Kern W, Haferlach T, Schnittger S, et al: Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol 22:2510-2511, 2004
2. Runde V, De Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome-Chronic Leukemia Working Party of the European Group of Blood and Marrow transplantation. Bone Marrow Transplant 21:255-261, 1998
3. Rowe JM: Therapy of secondary leukemia. Leukemia 16:748-750, 2002
4. Pulsoni A, Pagano L, Lo Coco F, et al: Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: The GIMEMA experience. Blood 100:1972-1976, 2002
5. Goldstone AH, Burnett AK, Avivi I, et al: Secondary acute myeloid leukemia has a worse outcome than de novo AML, even taking into account cytogenetics and age: AML 10, 11, 12 MRC Trials. Blood 100:88a, 2002 (abstr 322)